The aim of this study was to assess the long-term prognosis , efficacy , and safety of combination therapy using ursodeoxycholic acid ( UDCA ) and bezafibrate ( BF ) for primary biliary cirrhosis ( PBC ) patients exhibiting dyslipidemia .